Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CONSTELLATION PHARMACEUTICALS, INC.

(CNST)
End-of-day quote Nasdaq  -  2021-07-13
33.99 USD   +0.06%
2022MorphoSys Out Licenses Pre-Clinical Oncology Program
CI
2021MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
AQ
2021MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million
MT
SummaryQuotesChartsNewsCompanyFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Constellation Pharmaceuticals : ASH 2020 MANIFEST Data- Investor Event Presentation

12/07/2020 | 07:23am EST

CPI-0610:

Update of Preliminary Data fromMANIFEST

Analyst/Investor Meeting on ASH 2020

Stellar Science, Breakthrough Medicine

December 7, 2020

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of

1995 that involve substantial risks and uncertainties, including statements regarding the implications of preliminary or interim clinical data, the Company's plans, strategies and prospects for its business and statements regarding the development status of the Company's

product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to: obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the final results of the trial; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of CPI-0610 and CPI- 0209; advance the development of its product candidates under the timelines it anticipates, or at all, in current and future clinical trials; obtain, maintain, or protect intellectual property rights related to its product candidates; manage expenses; raise the substantial additional capital needed to achieve its business objectives; the COVID-19 pandemic and general economic and market conditions. CPI-0610 and CPI-

0209 are investigational therapies and have not been approved by the FDA (or any other regulatory authority). For a discussion of other risks and uncertainties, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's

most recent filings with the Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

2

MANIFEST at ASH 2020

Constellation Pharmaceuticals Analyst/Investor Meeting

Jigar Raythatha

Jeffery Humphrey, M.D.

Katarina Luptakova, M.D.

Patrick Trojer, Ph.D.

President and CEO

Chief Medical Officer

VP, Clinical Development

Chief Scientific Officer

John Mascarenhas, M.D.

Srdan Verstovsek, M.D.

Associate Professor of Medicine

Professor of Medicine

Icahn School of Medicine at Mount Sinai - New York

University of Texas MD Anderson Cancer Center

3

Agenda

Topic

Presenter

Company Profile

Jigar Raythatha

Unmet Need in Myelofibrosis (MF)

Highlights of CPI-0610 ASH data

Jeff Humphrey

MANIFEST Clinical Data

Katarina Luptakova

MANIFEST Translational Data

Patrick Trojer

KOL Panel

Moderator: Jigar Raythatha

KOLs: John Mascarenhas

Srdan Verstovsek

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Constellation Pharmaceuticals Inc. published this content on 07 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 December 2020 12:22:07 UTC


ę Publicnow 2020
All news about CONSTELLATION PHARMACEUTICALS, INC.
2022MorphoSys Out Licenses Pre-Clinical Oncology Program
CI
2021MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,3..
AQ
2021MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million
MT
2021MorphoSys AG
AQ
2021Sector Update: Health Care Stocks Lower Just Ahead of Closing Bell
MT
2021Sector Update: Health Care Stocks Lacking Much Traction
MT
2021Constellation Pharmaceuticals : Completion of Acquisition or Disposition of Assets (Form 8..
PU
2021Constellation Pharmaceuticals Inc : Completion of Acquisition or Disposition of Assets, No..
AQ
2021Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financ..
CI
2021Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief E..
CI
More news
Analyst Recommendations on CONSTELLATION PHARMACEUTICALS, INC.
More recommendations
Chart CONSTELLATION PHARMACEUTICALS, INC.
Duration : Period :
Constellation Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Lara Smith-Weber President, Secretary & Treasurer
Kathleen Warnecke Director
Kia Khalaghpour Vice President-Investor Relations & Communications
Brad Prosek Chief Business Officer
Richard Mountfield Senior Vice President-Regulatory Affairs & Quality
Sector and Competitors
1st jan.Capi. (M$)
CONSTELLATION PHARMACEUTICALS, INC.0.00%1 625
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.15.90%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436